Allogeneic haemopoietic cell transplants in Australia, 1996 - A multicentre retrospective comparison of the use of peripheral blood stem cells with bone marrow

Bone Marrow Transplantation

Volumn 28, Issue 1, 2001, Pages 21-27

  Nivison Smith, I ^a   Bradstock, K F ^b   Szer, J ^c   Durrant, S ^d   Dodds, A ^a   Hermann, R ^e   Schwarer, A P ^f   Gibson, J ^g   To, L B ^h   Arthur, C ⁱ  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Allogeneic bone marrow transplantation; Graft versus host disease; Peripheral blood stem cells

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; MELPHALAN; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUSTRALIA; BIOLOGICAL THERAPY; BLEEDING; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR; FEMALE; FOLLOW UP; GENDER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERMETHOD COMPARISON; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASIA; MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; THALASSEMIA; THROMBOCYTE; TIME; VEIN OCCLUSION; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AUSTRALIA; BLOOD CELLS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME;

EID: 0034894512     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703088     Document Type: Article

References (38)

1. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
2. G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
3. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF
4. Lenograstim administration to HLA-identical donor-recipient pairs to accelerate marrow recovery post-transplant
5. Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
6. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
7. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - An analysis of kinetics of engraftment and GVHD risk
8. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases
9. Allogeneic blood stem cell transplantation: Considerations for donors
10. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
11. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Marrow Transplantation
12. Instructions for completing reporting forms for Initial report of transplant for leukemia, lymphoma or other malignant disease
13. Non-parametric estimation from incomplete observations
14. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow marrow speeds engraftment of neutrophils and platelets without additional graft-versus-host disease: Results of a randomised clinical trial
15. Allogeneic transplants with peripheral blood progenitor cells: A report of six cases
16. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors
17. Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children with haematological malignancies
18. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors
19. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
20. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
21. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy
22. Partially mismatched blood cell transplants for high-risk hematologic malignancy
23. Allogeneic peripheral blood stem cell transplantation is not associated with a high risk of chronic graft-versus-host disease (cGVHD)
24. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study
25. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case control study
26. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs-host disease and relapse
27. Long-term follow-up of high-risk allogeneic peripheral blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality
28. Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia
29. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: A single-center experience
30. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation
31. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
32. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle
33. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
34. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow leukemia
35. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
36. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease
37. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation
38. Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion